OrexiCAR T cells potentiate the antitumor efficacy of rituximab. (A) NSG mice that received engraftment with a 1:2 ratio of Nalm6-GFP/Luc and Nalm6-CD19KO-GFP/Luc were treated with WT or OrexiCAR T cells. (B) Loss of CD19 expression in Nalm6 KO was confirmed via flow cytometry. (C) Tumor burden at day 9 after engraftment was quantified using BLI and normalized to highest tumor burden. Combined 2 independent experiments. (D) Survival curves for treated mice from 2 independent experiments. (E) NSG mice that underwent engraftment with Raji-GFP/Luc tumor cells IP were treated with 5e5 WT or OrexiCAR T cells and subsequently treated with rituximab or control antibody. (F) Tumor burden was measured over time using BLI (median tumor burden line is drawn) and shown for day 86 after engraftment in (G). (H) Combined survival curves for treated mice from 2 to 3 independent experiments. Statistics were performed using Student t test or log-rank survival analysis.